Latest Breaking News On - Lisa raffensperger - Page 1 : comparemela.com

SOTIO Biotech: SOTIO Announces First Patient Dosed in Phase 1 Clinical Study of SOT201 for Patients with Solid Tumors

Novel immunocytokine utilizes dual mechanisms of action to activate immune system to fight solid tumors Company has received IND and CTA approval to initiate Phase 1 study in the U.S. and

United statesCzech republicMaung naingLisa raffenspergerRichard sachseRichard kapsaUniversity of texas md anderson cancer centerCancer centerIhr portfolio

Epic Bio to Participate in Fireside Chat at Stifel s Genetic Medicines Forum | Region

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, announced

Benson chengLisa raffenspergerAmber salzmanGenetic medicines forumAnnual genetic medicines forumGene expression modulation system

SOTIO Biotech: SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting

Patient enrollment and dosing ongoing in first-in-human study of BOXR1030 enhanced CAR T-cell therapy SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, will present

United statesEcaterina dumbravaLisa raffenspergerRichard kapsaUniversity of texas md anderson cancer centerAmerican society of clinical oncologyClinical oncologyAssistant professorInvestigational cancer therapeuticsCancer centerIhr portfolio

SOTIO Biotech: SOTIO to Present Poster on DUET-01 Clinical Trial at 2024 ASCO Annual Meeting

SOTIO Biotech: SOTIO to Present Poster on DUET-01 Clinical Trial at 2024 ASCO Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesLisa raffenspergerRichard kapsaDennis riedlAmerican society of clinical oncologyClinical oncologyAnnual meetingAktien sie

Epic Bio Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform Leadership at ASGCT Annual Meeting

Epic Bio Presents New Data Highlighting Potential of EPI-321 for FSHD and Epigenetic Editing Platform Leadership at ASGCT Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesLisa raffenspergerAmber salzmanShawnm coxCorporate communicationsBio presents new data highlighting potentialEpigenetic editing platform leadershipAnnual meetingAmerican societyCell therapyEpic bioGene expression modulation systemInvestor relations